Aranesp and Hyperthyroidism - a phase IV clinical study of FDA data

Summary:

Hyperthyroidism is reported as a side effect among people who take Aranesp (darbepoetin alfa), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Innohep, and have Anaemia.

The phase IV clinical study analyzes which people have Hyperthyroidism when taking Aranesp. It is created by eHealthMe based on reports of 54,218 people who have side effects when taking Aranesp from the FDA, and is updated regularly.

What is Aranesp?

Aranesp has active ingredients of darbepoetin alfa. It is often used in anemia. eHealthMe is studying from 54,331 Aranesp users. Check the latest studies of Aranesp.

What is Hyperthyroidism?

Hyperthyroidism (over activity of the thyroid gland) is found to be associated with 977 drugs and 1,437 conditions by eHealthMe. Check the latest studies of Hyperthyroidism.

On Jul, 20, 2026

54,218 people reported to have side effects when taking Aranesp.
Among them, 38 people (0.07%) have Hyperthyroidism.

Among these 38 people:

How long have people been on Aranesp when they have Hyperthyroidism? *

What is the gender of people who have Hyperthyroidism when taking Aranesp? *

female: 61.11 %
male: 38.89 %

What is the age of people who have Hyperthyroidism when taking Aranesp? *

What are other drugs people take besides Aranesp? *

What are other side effects people have besides Hyperthyroidism? *

Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 13 people, 34.21%
Diarrhea: 12 people, 31.58%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 11 people, 28.95%
Chest Pain: 11 people, 28.95%
Cough: 11 people, 28.95%
Insomnia (sleeplessness): 11 people, 28.95%
Stress And Anxiety: 9 people, 23.68%
Pain: 9 people, 23.68%
Herpes Zoster: 9 people, 23.68%
Pneumonia: 9 people, 23.68%

What are the existing conditions these people have? *

Anaemia (lack of blood): 10 people, 26.32%
Conjunctival Haemorrhage (bleeding underneath the conjunctiva): 8 people, 21.05%
Lung Neoplasm Malignant (cancer tumour of lung): 8 people, 21.05%
High Blood Pressure: 5 people, 13.16%
Primary Myelofibrosis (primary disorder of the bone marrow): 5 people, 13.16%
Extrasystoles: 5 people, 13.16%
Hypokalemia (low potassium): 5 people, 13.16%
Breast Cancer: 4 people, 10.53%
Diabetes: 4 people, 10.53%
Gastroduodenitis (an inflammation of the mucous membrane of the stomach and duodenum): 4 people, 10.53%

* Approximation only. Some reports may have incomplete information.

Do you take Aranesp and have Hyperthyroidism?

- Check whether Hyperthyroidism is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Aranesp:

Aranesp (54,331 reports)

Hyperthyroidism treatments and more:

Hyperthyroidism (26,832 reports)

Browse all side effects of Aranesp:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperthyroidism:

Hyperthyroidism (977 drugs)

Browse all the conditions that are associated with Hyperthyroidism:

Hyperthyroidism (1,437 conditions)

Related publications that referenced our studies

Dulani S, Dulani R, Lele S, Diagavane S, Anjankar S, Jaiswal N, Subramaniam PS, Juneja R, "Chronic Subdural Haematoma in a Case of Hyperthyroidism Presenting with Papilledema", Chinese Medicine, 2012 Dec .
Dulani S, Dulani R, Lele S, Diagavane S, Anjankar S, Jaiswal N, Subramaniam PS, Juneja R, "Chronic Subdural Haematoma in a Case of Hyperthyroidism Presenting with Papilledema", Chinese Medicine, 2012 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on darbepoetin alfa (the active ingredients of Aranesp) and Aranesp (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.